News

Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019

BOULDER, Colo., Jan. 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019. Ron Squarer, Chief Executive Officer, will lead the call.

Date:

Tuesday, February 5, 2019

Time:

9:00 a.m. Eastern Time

Toll-Free:

(844) 464-3927

Toll:

(765) 507-2598

Pass Code:

9778144

Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/5zkxjoof

About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi® (larotrectinib, partnered with Loxo Oncology) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com

Array BioPharma. (PRNewsFoto/Array BioPharma Inc.) (PRNewsFoto/)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2019-on-february-5-2019-300786082.html

SOURCE Array BioPharma

ShareThis Copy and Paste